Literature DB >> 4889342

Parkinsonism and DOPA.

G C Cotzias, P S Papavasiliou, R Gellene, R B Aronson.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1968        PMID: 4889342

Source DB:  PubMed          Journal:  Trans Assoc Am Physicians        ISSN: 0066-9458


× No keyword cloud information.
  6 in total

1.  [Differential treatment of Parkinson's disease, with special reference to the possibility of iatrogenic disorders (author's transl)].

Authors:  W Gehlen
Journal:  Arch Psychiatr Nervenkr (1970)       Date:  1974-04-09

2.  Miosis during L-dopa therapy.

Authors:  A S Spiers; D B Calne; P M Fayers
Journal:  Br Med J       Date:  1970-06-13

3.  [Long-term treatment with L-DOPA in a case of torsion dystonia (authors transl)].

Authors:  W Winkelmann
Journal:  J Neurol       Date:  1975       Impact factor: 4.849

Review 4.  L-dopa therapy in Parkinson's disease: a critical review of nine years' experience.

Authors:  A Barbeau
Journal:  Can Med Assoc J       Date:  1969-12-27       Impact factor: 8.262

5.  Hypotension caused by L-dopa.

Authors:  D B Calne; J Brennan; A S Spiers; G M Stern
Journal:  Br Med J       Date:  1970-02-21

6.  Quantitative analysis of the therapeutic effect of magnolol on MPTP-induced mouse model of Parkinson's disease using in vivo 18F-9-fluoropropyl-(+)-dihydrotetrabenazine PET imaging.

Authors:  Chi-Chang Weng; Zi-An Chen; Ko-Ting Chao; Ting-Wei Ee; Kun-Ju Lin; Ming-Huan Chan; Ing-Tsung Hsiao; Tzu-Chen Yen; Mei-Ping Kung; Ching-Han Hsu; Shiaw-Pyng Wey
Journal:  PLoS One       Date:  2017-03-03       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.